NRXBF and J90 Related Headlines
Go Back- NurExone names David Stolick to board, hires investor firm
- Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
- NurExone closes private placement raising C$627,795
- NurExone Announces Closing of Non-Brokered Private Placement
- NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
- NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
- Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
- NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
- NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
- NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
- NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
- NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
- NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
NRXBF and J90 Related Press Releases
Go Back- Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
- NurExone Announces Closing of Non-Brokered Private Placement
- NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
- NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
- Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
- NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
- NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
- NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
- NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
- NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
- NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
